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ABSTRACT
ObjectivesToestimatehowmanypeopleobjecttostorage
of biological samples collected in health care in Sweden
and to their use in research and how many withdraw
previous consent.
Design Cross sectional study of register data.
Setting Biobanks used in Swedish health care, 2005-6.
Population Data on refusal to consent were obtained for
1.4 million biobank samples per year from 20 of 21
counties.
Main outcome measures Rates of preliminary refusal to
consent, confirmed refusal, and withdrawal of consent.
Results Patients refused consent to either storage or use
of their samples in about 1 in 690 cases; about 1 in 1600
confirmed their decision by completing a dissent form.
Rather than having the samples destroyed, about 1 in
6200 patients wanted to restrict their use. Of those who
had previously consented, about 1 in 19000 withdrew
their consent.
Conclusions Refusal to consent to biobank research in
Sweden is rare, and the interests of individuals and
research interests need not be at odds. The Swedish
healthcare organisation is currently obliged to obtain
either consent or refusal to each potential use of each
sample taken, and lack of consent to research is used as
the default position. A system of presumed consent with
straightforward opt out would correspond with people’s
attitudes, as expressed in their actions, towards biobank
research.
INTRODUCTION
Erosion of trust
1-3 in health care and medical science
could have severe consequences for medical
research.
4-6 Some studies, however, do not support
these concerns.
47-10 A recent overview of international
surveys found that at least 80% of people are willing to
donate biological material for research.
11 Willingness
might be even higher in Sweden.
12-14 Most Swedes
seem to prefer general, one time consent in this
context.
515 People might be less concerned in their
dailylifeaboutrisksentailedbybiobankresearchthan
they claim to be in surveys.
WedeterminedtheextenttowhichSwedishpatients
refused consent to storage or restricted the use of
samples taken in public health care in 2005 and 2006;
whetherthisposesanactualthreattobiobankresearch;
and whether trust in biobank research associated with
Swedish health care is eroding.
METHODS
Our targets were biobanks used in health care across
the country. We did not include biobanks used
exclusively for research or material from blood
donations, autopsies, and fetal and infant screening.
Patients can express preliminary refusal to consent
eitherwhensamplesaretakenorlaterbycontactingthe
county’s biobank coordinator. In either case, refusal-
must be confirmed by submitting a “dissent form”
specifyingthenatureoftherefusal(tostorage,research,
or some particular use). We asked biobank registers
across the country for data on confirmed refusal
toconsentand the number of laboratory referrals,
which is equal to or less than the number of samples,
in 2005 and 2006. We obtained full data for 13 of 21
counties, and partial coverage for seven; one county
was unable to comply with the request.
Data were separated into series by sample type (for
example, histopathological biopsies and cervical
screening smears) and geographical location. Vari-
ables were expressed as percentages of the number of
referrals. For each calculation, we excluded those and
only those sample series for which the numerator was
missing. We detected changes in overall ratios over
timewithχ
2testwithcontinuitycorrection.Wedidnot
test for differencesseries by series, because they varied
almost 700-fold in size.
RESULTS
During 2005-6, about 1 in 690 potential donors
expressed preliminary refusal to consent. Of these,
about halfconfirmed their decision. A quarter of those
whoconfirmedtheirrefusalwantedtorestricttheuseof
samples rather than having them destroyed, and 1 in
19000 patients who initially consented withdrew their
consent. The table summarises the main findings .
The main causes of “drop out” from future research
(fig 1) were inability to consent (0.25%) and system
errors (0.26%); the former increased (from 0.20% to
0.29%, P<0.001) from 2005 to 2006, while the latter
droppeddramatically(from0.33%to0.19%,P<0.001)
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by variations in follow-up practices and errors in
reporting(forexample,usingthe“inabilitytoconsent”
category for indecisive patients or use of obsolete
referral forms). Between sample types, refusal to
consent was most common in the cervical screening
subgroup (0.10%; fig 2).
Preliminary rates of refusal to consent were particu-
larly high in one pathology laboratory (794/207866
(0.38%) in 2005 and 902/210980 (0.43%) in 2006);
however,onlyatenthofthesepatientsconfirmedtheir
decisions. Regarding confirmed refusal, we identified
extreme outliers in two small series of seminal fluid
samples (8/307 (2.6%) in 2005 and 8/403 (1.9%) in
2006).
DISCUSSION
Fewer than 700 in one million Swedes actively oppose
storageofor researchusingbiobanksamplescollected
in routine health care. Most of them refuse consent to
storage, which is consistent with previous findings that
privacyisimportantwhereasthepurposeofresearchis
a lesser concern.
111516 The threat posed to quality of
research is arguably minimal.
Webelievethatourresults,althoughnotnecessarily
generalisable to other contexts or cultures, are
RefusaltoconsenttostorageanduseofbiobanksamplesinSwedenin2005and2006
Sample series
included*
2005 2006
Rate Rate in % (95% CI) IQR for rate Rate Ratein%(95%CI) IQR for rate
Preliminaryrefusaltoconsent 72 1656/1 191 176 0.139 (0.132 to
0.146)
0.031-0.123 1806/1 208 717 0.149 (0.143 to
0.156)
0.022-0.097
Confirmed refusal to consent 83 954/1 442 998 0.066 (0.062 to
0.070)
0.000-0.075 888/1 466 659 0.061 (0.057 to
0.065)
0.007-0.056
Specific refusal to consent 79 224/1 401 572 0.016 (0.014 to
0.018)
0.000-0.019 234/1 424 517 0.016 (0.014 to
0.019)
0.000-0.017
Withdrawal of consent 69 66/1 168 634 0.0056 (0.0043 to
0.0070)
0.0000-0.0061 58/1 194 676 0.0049 (0.0036 to
0.0061)
0.0000-0.0049
Unable to consent 73 2469/1 218 372 0.20 (0.19 to 0.21) 0.00-0.23 3639/1 239 765 0.29 (0.28 to 0.30) 0.00-0.09
System error 74 4049/1 213 496 0.33 (0.32 to 0.34) 0.00-0.02 2376/1 236 391 0.19 (0.18 to 0.20) 0.00-0.00
IQR=interquartile range.
*Not all 83 sample series (groups of samples by type and geographical location) had data for each variable. Several rates fall outside corresponding interquartile ranges, which reflects
presence of influential outliers.
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Fig1 |Datafromall83seriesperyear.Noteveryserieshaddata
on system errors andinability to consent; missing values have
beenextrapolated. Not all registers specified whether patients
refused consent early or late, so some withdrawals might be
hidden in the “timing unknown” category
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Fig 2 | Data from 73 series per year that contained single,
predefinedsampletypes.Patientsmostlikelytorefuseconsent
werewomenundergoingscreeningforprecancerouschangesin
cervix. In the clinical genetics category, interpretation is
difficult because of small number of referrals (<8000/year); in
absolute numbers, bars represent one and three cases of
dissent, respectively. Other categories are larger (from 48000
to >500000 samples/year)
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page 2 of 3 BMJ | ONLINE FIRST | bmj.comrepresentative of patients in Sweden. The geographic
coverage was sufficient. The age distribution might be
skewedaselderlypeoplearemorefrequentconsumers
of health care. Even among young to middle aged
women in the cervical screening subgroup, however,
the rates of refusal to consent were only about 0.1%.
One concern has been that refusal to consentcould
be underestimated if several samples requiring sepa-
rate referrals are taken in one session but the patient
submits only one form to cover them all. While such a
distortion might affect serological examinations, it is
probably less pronounced for the other sample types.
Many people are unfamiliar with biobanks and
might be underinformed about their rights and the
possible implications of storing biological material.
Still, people are becoming increasingly well informed
through other channels, such as television, news-
papers, the internet, and posters in waiting rooms. If
people were concernedabout their samples, we would
expect more of them to refuse consent over time.
Because of the short time frame our results do not
exclude the possibility of such a trend, but neither do
they support it.
Trust in health care and research
While our results tell us what patients do, they may
indicate little of what they think. Surveys based on
hypothetical situations, though with problems of their
own,
1718mightprovidemorereliablemeasuresoftrust.
On the other hand, if we believe that there is a
connection between attitudes of trust and trusting
behaviour, and, more particularly, assumingthat most
people with deeply felt distrust will not, given the
choice, place trust,
19 our results give us no reason to
believe that distrust is widespread.
Acomplexandcostlyadministrationhasbeensetup
to protect the small minority of patients who do not
want their samples to be stored in biobanks or used in
research. The right to say “no” might be justified, no
matter how small the minority utilising it,
20 but the
means chosen to protect it seem flawed. A system that
consumes resources from public health care
21 and
imposesabureaucracywithnobenefits,whilepossibly
still failing to inform people of their rights, is not likely
to evoke the trust so urgently needed.
22 Though
informed consent in biobank research is a complex
issue
23thatwarrantsfurtherresearch,thepresentstudy
gives some reasons to consider an alternative system,
where consent would be presumed, information read-
ily available, and opting out straightforward.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Therightofpatientstorefuseconsenttotheuseoftheirbiologicalsamplesinresearch,andthe
right to withdraw previous consent, could harm quality of research
The threat could be even greater if trust in medical research and health care is eroding
WHAT THIS STUDY ADDS
During 2005 and 2006 in Sweden, for 1.4 million samples the rate of confirmed refusal to
consentwas1in1600forstorageoruseinresearch,and1in19000peoplewithdrewprevious
consent
Thesefiguressuggestnoimmediatethreattobiobankresearchandnocrisisoftrustinresearch
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